N-Ethyl-N-3-((3-dimethylamino-1-oxo-2-propenyl)phenyl)acetamide, bearing the CAS number 96605-66-2, is more than just a chemical compound; it is a critical enabler in the pharmaceutical industry, particularly for the production of Zaleplon. This non-benzodiazepine hypnotic agent, used for short-term treatment of insomnia, relies heavily on the availability of high-purity intermediates like this one. Understanding its chemical characteristics, synthesis routes, and how to effectively source it is vital for pharmaceutical researchers and manufacturers.

The compound is typically described as a yellow crystalline powder, with a purity assay of ≥98.0%. Its physical and chemical properties, such as density and boiling point, are well-documented, providing a solid foundation for its use in controlled synthetic processes. The complex structure of N-Ethyl-N-3-((3-dimethylamino-1-oxo-2-propenyl)phenyl)acetamide allows it to serve as a specific precursor in the multi-step synthesis of Zaleplon. The efficiency and yield of the final API are directly influenced by the quality of this intermediate, highlighting the importance of meticulous production standards.

When considering where to buy N-Ethyl-N-3-((3-dimethylamino-1-oxo-2-propenyl)phenyl)acetamide, the global market offers various options. However, the expertise and manufacturing capabilities found in China make it a primary hub for sourcing such specialized chemicals. A reliable pharmaceutical intermediates manufacturer China possesses the technical know-how and infrastructure to produce this compound consistently and at scale. They adhere to strict quality control protocols, ensuring that each batch meets the required specifications, thereby supporting the uninterrupted production of Zaleplon and similar pharmaceuticals.

The process of N-Ethyl-N-3-((3-dimethylamino-1-oxo-2-propenyl)phenyl)acetamide synthesis involves advanced organic chemistry techniques. Manufacturers often refine these processes to improve yield and purity. For procurement managers and R&D scientists, understanding these synthesis pathways can inform sourcing decisions. Access to detailed technical data, Certificates of Analysis (CoA), and dependable supplier relationships are crucial. By securing a stable supply of this key Zaleplon intermediate, pharmaceutical companies can ensure the continuity of their production lines and maintain the high standards expected in the healthcare sector.